Niagen Bioscience (NAGE)
Builds Niagen-based supplements, ingredients, and clinical NAD+ channels.
$3.05
vs last close−0.04 (−1.27%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19 | 21 | 22 | 23 | 26 | 29 | 30 | 31 | 34 | 34 | 31 | 30 |
| Cost of revenue | 8 | 8 | 9 | 9 | 9 | 11 | 11 | 11 | 12 | 12 | 11 | 10 |
| Gross profit | 12 | 13 | 13 | 14 | 16 | 18 | 19 | 20 | 22 | 22 | 20 | 19 |
| 13 | 13 | 14 | 14 | 15 | 11 | 15 | 17 | 18 | 20 | 18 | 19 | |
| Research & development | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 |
| 12 | 12 | 12 | 13 | 13 | 10 | 13 | 15 | 16 | 18 | 17 | 17 | |
| Selling & marketing | 6 | 7 | 7 | 7 | 7 | 9 | 8 | 8 | 9 | 10 | 10 | 10 |
| General & administrative | 6 | 5 | 5 | 6 | 6 | 1 | 5 | 7 | 7 | 7 | 7 | 7 |
| Operating income | −1 | 0 | −1 | 0 | 2 | 7 | 5 | 3 | 4 | 2 | 2 | 1 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 5 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | −1 | −2 | −5 | 0 |
| Income before tax | −1 | 0 | 0 | 0 | 2 | 7 | 5 | 4 | 5 | 4 | 7 | 1 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −1 | 0 | 0 | 0 | 2 | 7 | 5 | 4 | 5 | 4 | 6 | 1 |
| Net income | −1 | 0 | 0 | 0 | 2 | 7 | 5 | 4 | 5 | 4 | 6 | 1 |
| EPS, basic | −$0.01 | $0.00 | −$0.01 | −$0.00 | $0.02 | $0.09 | $0.07 | $0.05 | $0.05 | $0.05 | $0.08 | $0.01 |
| EPS, diluted | −$0.01 | $0.00 | −$0.01 | −$0.00 | $0.02 | $0.09 | $0.06 | $0.04 | $0.05 | $0.05 | $0.07 | $0.01 |
| Weighted average shares, basic | 75 | 73 | 75 | 76 | 78 | 77 | 78 | 79 | 87 | 79 | 80 | 79 |
| Weighted average shares, diluted | 75 | 75 | 75 | 76 | 78 | 82 | 83 | 86 | 87 | 84 | 85 | 83 |
| EBITDA | −1 | 0 | 0 | 0 | 2 | 8 | 6 | 4 | 5 | 5 | 7 | 1 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| EBIT | −1 | 0 | 0 | 0 | 2 | 7 | 5 | 4 | 5 | 4 | 7 | 1 |